Precipio IncNASDAQ:PRPONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9500
- TODAY'S CHANGE (%)0.0400 (4.3956%)
- Bid / Lots0.9401/ 1
- Ask / Lots0.9650/ 20
- Open / Previous Close0.9799 / 0.9100
- Day Range
- 52 Week Range
- Volume163,358
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRPO |
|---|---|---|
| 09:32 ET | 19913 | 0.9798 |
| 09:33 ET | 20829 | 0.9102 |
| 09:35 ET | 700 | 0.97 |
| 09:39 ET | 349 | 0.9107 |
| 09:42 ET | 200 | 0.95 |
| 09:44 ET | 4104 | 0.94 |
| 09:46 ET | 2910 | 0.9101 |
| 09:48 ET | 4714 | 0.94 |
| 10:02 ET | 2675 | 0.95 |
| 10:04 ET | 9150 | 0.94 |
| 10:06 ET | 1800 | 0.9102 |
| 10:08 ET | 350 | 0.9102 |
| 10:15 ET | 13400 | 0.9105 |
| 10:22 ET | 20150 | 0.92 |
| 10:24 ET | 600 | 0.9301 |
| 10:26 ET | 800 | 0.9401 |
| 10:33 ET | 1100 | 0.92 |
| 10:36 ET | 100 | 0.9299 |
| 10:40 ET | 1100 | 0.9207 |
| 10:42 ET | 400 | 0.92 |
| 10:54 ET | 5082 | 0.91 |
| 10:56 ET | 576 | 0.9005 |
| 10:58 ET | 800 | 0.9098 |
| 11:02 ET | 2624 | 0.9199 |
| 11:03 ET | 2600 | 0.9175 |
| 11:12 ET | 1500 | 0.9419 |
| 11:20 ET | 100 | 0.9499 |
| 11:34 ET | 500 | 0.95 |
| 11:43 ET | 14855 | 0.9338 |
| 11:54 ET | 2250 | 0.9338 |
| 11:56 ET | 2000 | 0.9338 |
| 12:10 ET | 500 | 0.96 |
| 12:17 ET | 3100 | 0.9575 |
| 12:19 ET | 2673 | 0.959899 |
| 12:21 ET | 1620 | 0.9578 |
| 12:24 ET | 2600 | 0.9578 |
| 12:26 ET | 1900 | 0.9599 |
| 12:30 ET | 880 | 0.955 |
| 12:32 ET | 3300 | 0.955 |
| 12:33 ET | 3976 | 0.94 |
| 12:44 ET | 903 | 0.94 |
| 12:51 ET | 317 | 0.95 |
Jan 11, 2023
BRIEF-Precipio Signs Another Major Hemescreen Customer, from 5:27PM ET on Wednesday Jan 11, 2023 by Thomson Reuters
5:27PM ET on Wednesday Jan 11, 2023 by Thomson ReutersPrecipio Sees Q1 Revenue Nearly Trebling After Signing Deal for HemeScreen Technology With New Customer; Shares Jump, from 12:10PM ET on Wednesday Jan 11, 2023 by MT Newswires
12:10PM ET on Wednesday Jan 11, 2023 by MT NewswiresPrecipio Signs Another Major HemeScreen(TM) Customer, from 10:00AM ET on Wednesday Jan 11, 2023 by GlobeNewswire
10:00AM ET on Wednesday Jan 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Precipio Inc | 20.8M | -1.8x | --- |
HTG Molecular Diagnostics Inc | 9.7M | -0.2x | --- |
Ekso Bionics Holdings Inc | 22.2M | -1.4x | --- |
Avinger Inc | 10.0M | -0.3x | --- |
Nuwellis Inc | 4.6M | -0.1x | --- |
Arypsa Inc | 8.5K | 0.0x | --- |
Company Information
Precipio, Inc. is a healthcare solutions company that is focused on cancer diagnostics. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
Contact Information
- Headquarters
- 12325 Emmet StOMAHA, NE, United States 68164-4243
- Phone
- 203-787-7888
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Sandberg
- Chief Executive Officer, Founder, Director
- Ilan Danieli
- Interim Chief Financial Officer
- Matthew Gage
- Chief Operations Officer
- Ahmed Zaki Sabet
- Chief Legal Counsel and People Officer
- Miri Chiko-radomski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.8M |
|---|---|
Revenue (TTM) | $9.5M |
Shares Outstanding | 22.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-0.53 |
Book Value | $1.08 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -141.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
